Drug intelligence / Profile preview

N-acetylcysteine + tigecycline + heparin

Development stage
Unknown
Lead developer
Galectin Therapeutics
Modality
Small Molecules
Administration
Intracatheter
01

Overview

N-acetylcysteine + tigecycline + heparin is a combination drug formulation used primarily as a catheter-lock solution for the treatment and prevention of catheter-associated bacteremia, particularly in patients with hemodialysis catheters. This combination leverages the synergistic effects of its components: - **N-acetylcysteine (NAC)** acts as a mucolytic and antioxidant agent that disrupts biofilm formation by breaking down extracellular polysaccharide matrices, thereby enhancing the penetration and efficacy of antibiotics against biofilm-embedded bacteria. - **Tigecycline** is a broad-spectrum glycylcycline antibiotic effective against multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis. It exhibits potent activity against both planktonic and biofilm-associated bacteria. - **Heparin** serves as an anticoagulant to maintain catheter patency during lock therapy. The combination has demonstrated synergistic antimicrobial activity in vitro and positive clinical outcomes in pilot trials for catheter salvage, with high rates of successful infection control without compromising anticoagulant function[1][2][4][5].

Other names
NAC/Tigecycline/Heparin combination lock solutionNAC-Tigecycline-Heparin lock solution
02

Targets

ATIII (Antithrombin III)Bacterial Ribosome

Beyond the preview

Go deeper on N-acetylcysteine + tigecycline + heparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-acetylcysteine + tigecycline + heparin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call